Real-World Experience of Pembrolizumab Monotherapy in Patients with Recurrent or Persistent Cervical Cancer: A Korean Multi-Center Retrospective Study (KGOG1041)

• Published in: Cancers Vol. 12; no. 11; p. 3188
• Main Authors: Choi, Min Chul, Kim, Yong-Man, Lee, Jeong-Won, Lee, Yong Jae, Suh, Dong Hoon, Lee, Sung Jong, Lee, Taek Sang, Lee, Maria, Park, Dong Choon, Kim, Min Kyu, Lee, Jong-Min, Shim, Seung-Hyuk, Jeon, Seob, Min, Kyung Jin, Kim, Mi Kyung, Kim, Bo Wook, Park, Jeong Yeol, Kim, Byoung-Gie, Kim, Dae Yeon, Kim, Moon-Hong, Kim, Hyun-Soo, Lee, Jung-Yun
• Format: Journal Article
• Language: English
• Published: MDPI AG 01.11.2020; MDPI
• Subjects: Cervical cancer; Drug therapy; Patient outcomes; South Korea
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers12113188

This study investigated the antitumor activity and safety of pembrolizumab in patients with recurrent cervical cancer in real-world practice. We conducted a multi-center retrospective study of patients with recurrent or persistent cervical cancer treated with pembrolizumab at sixteen institutions in Korea between January 2016 and March 2020. The primary endpoints were the objective response rate (ORR) and safety. Data were available for 117 patients. The median age was 53 years (range, 28–79). Sixty-four (54.7%) patients had an Eastern Cooperative Oncology Group (ECOG) performance status of ≥2. Forty-nine (41.9%) patients were stage ≥III at diagnosis. Eighty-eight (75.2%) patients had squamous cell carcinoma. The median number of prior chemotherapy lines was two (range, 1–6). During the median follow-up of 4.9 months (range, 0.2–35.3), the ORR was 9.4%, with three complete responses and eight partial responses. The median time to response was 2.8 months (range 1.3–13.1), and the median duration of response (DOR) was not reached. In the population of patients with favorable performance status (ECOG ≤1) (n = 53), the ORR was 18.9%, and the median DOR was 8.9 months (range, 7.3–10.4). Adverse events occurred in 55 (47.0%) patients, including eight (6.8%) patients who experienced grade ≥3 events, and two of them were suspicious treatment-related deaths. Pembrolizumab had modest antitumor activity in patients with recurrent cervical cancer comparable to that found in previously reported clinical trials. However, in patients with favorable performance status, pembrolizumab showed effective antitumor activity. Some safety profiles should be carefully monitored during treatment.